Immune Monitoring in Cancer

Immunity-informed Decisions for Cancer Treatment

Obtain valuable insights from patients under treatment

Detailed monitoring of cancer-specific T-cell populations in patients undergoing treatment provides insights into existing or induced immunity. Those insights define the properties of a patient’s cellular immune response to different treatments that may correlate with therapy success.

Immudex has predefined Dextramer® panels for flow cytometry to detect, quantify or isolate cancer-specific T-cell population subsets in peripheral blood or tumor biopsies. Alternatively, select antigens of interest from our menu or define custom Dextramer® reagents.

The Melanoma Dextramer® Panel

Melanoma is a malignant neoplasm of melanocytes arising de novo or from a benign nevus. Tumor-reactive T cells specific for a range of melanoma-associated antigens have been isolated from melanoma patients. Important melanoma-antigens include melanocyte lineage proteins like Tyrosinase, gp100, MART-1, and Cancer-Testis antigens like the MAGE proteins and NY-ESO-1. These are all potentially suitable targets for tumor vaccines because of their high immunogenicity in vivo and their restricted distribution in normal tissue. Immune monitoring and quantification of antigen-specific CD8+ T cells that can recognize these antigens can provide information about melanoma-specific immunity.

Detect tumor-reactive T cells with specificity for 6 melanoma-associated antigens.

Order MHC Dextramer® Melanoma Panel

The panel contains melanoma-specific MHC I Dextramer reagents that display epitopes from six different melanoma-associated antigens. 

Each specificity is provided as a PE- and APC conjugate, enabling for so-called 2D-staining, i.e. the use of two Dextramer® with the same specificity but different fluorochromes in the same staining reaction.

2D-staining makes it easier to distinguish Dextramer®-positive cells from Dextramer®-negative cells. The use of dual-color staining has been demonstrated to reduce the frequency of false positives 10-fold1. The Panel also includes two negative control Dextramer® reagents.

Cat. no RX01 - Melanoma-specific Dextramer®

MHC Allele
Peptide Fluorophore Antigen Tests*
HLA-A*0201 ELAGIGILTV PE MART-1 25 tests
HLA-A*0201 ELAGIGILTV APC MART-1 25 tests
HLA-A*0201 SLLMWITQV PE NY-ESO-1 25 tests
HLA-A*0201 SLLMWITQV APC NY-ESO-1 25 tests
HLA-A*0201 KVAELVHFL PE MAGE-A3 25 tests
HLA-A*0201 KVAELVHFL APC MAGE-A3 25 tests
HLA-A*0201 YMDGTMSQV PE Tyrosinase 25 tests
HLA-A*0201 YMDGTMSQV APC Tyrosinase 25 tests
HLA-A*0201 IMDQVPFSV PE gp100 25 tests
HLA-A*0201 IMDQVPFSV APC gp100 25 tests
HLA-A*0201 KVLEYVIKV PE MAGE-A1 25 tests
HLA-A*0201 KVLEYVIKV APC MAGE-A1 25 tests
HLA-A*0201 Negative Control PE  - 25 tests
HLA-A*0201 Negative Control APC  - 25 tests

* One test is defined as 10 µl MHC Dextramer® reagent sufficient to stain up to 1-3 x 10^6 lymphoid cells or 1-3 x 10^5 clonal antigen-specific T cells.

The MHC Dextramer® Melanoma Panel is for research use only.

Immudex has updated the catalog numbers. To learn more about it, please consult the document here

The Cancer-Testis Antigens Dextramer® Panel

Cancer-Testis antigens (CTA) constitute a family of proteins that exhibit a remarkably restricted expression in gametogenic tissue and are consequently not exposed to the systemic immune system. This means that no immunological tolerance is established. CTA is over-expressed, and cellular immune responses have been reported in patients with a variety of tumors.

Identify immunity elicited by cancer-testis antigen (CTA) by quantifying CD8+ T cells that recognize these antigens.

Order MHC Dextramer® Cancer-Testis Antigens Panel

 

Immune monitoring and quantification of antigen-specific CD8+ T cells that can recognize these antigens can provide information about CTA-specific immunity.

Each specificity is provided as a PE- and APC conjugate, enabling for so-called 2D-staining, i.e. the use of two Dextramer® with the same specificity but different fluorochromes in the same staining reaction. 2D-staining makes it easier to distinguish Dextramer®-positive cells from Dextramer®-negative cells. The use of dual-color staining has been demonstrated to reduce the frequency of false positives 10-fold1.
The Panel also includes two negative control Dextramer® reagents.

Cat. No. RX02 - CTA-specific Dextramer®

MHC Allele
Peptide
Fluorophore Antigen Tests*
HLA-A*0201 SLLMWITQV PE NY-ESO-1 25 tests
HLA-A*0201 SLLMWITQV APC NY-ESO-1 25 tests
HLA-A*0201 KVAELVHFL PE MAGE-A3 25 tests
HLA-A*0201 KVAELVHFL APC MAGE-A3 25 tests
HLA-A*0201 KVLEYVIKV PE MAGE-A1 25 tests
HLA-A*0201 KVLEYVIKV APC MAGE-A1 25 tests
HLA-A*0201 Negative Control PE  - 25 tests
HLA-A*0201 Negative Control APC  - 25 tests

* One test is defined as 10 µl MHC Dextramer® reagent sufficient to stain up to 1-3 x 10^6 lymphoid cells or 1-3 x 10^5 clonal antigen-specific T cells.

The MHC Dextramer® Cancer-Testis Antigens Panel is for research use only.

Immudex has updated the catalog numbers. To learn more about it, please consult the document here

Pick-and-choose existing Dextramer® reagents

Select Dextramer® reagents from our extensive menu to match specific monitoring criteria. Enter “Cancer” or “Melanoma” in the category filter.

Define your own Dextramer® reagents

Select MHC alleles from our catalog and combine them with peptides to form stable complexes as tailored Dextramer® reagents.

1. Hadrup, S., et al, Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. 2009. Nature Methods, 6(7): p.520-28.